5.95
price up icon1.88%   0.11
after-market Handel nachbörslich: 5.91 -0.04 -0.67%
loading
Schlusskurs vom Vortag:
$5.84
Offen:
$5.82
24-Stunden-Volumen:
3.87M
Relative Volume:
0.88
Marktkapitalisierung:
$1.88B
Einnahmen:
$493.67M
Nettoeinkommen (Verlust:
$-104.69M
KGV:
-17.50
EPS:
-0.34
Netto-Cashflow:
$-31.51M
1W Leistung:
+5.12%
1M Leistung:
-3.41%
6M Leistung:
-36.09%
1J Leistung:
-39.59%
1-Tages-Spanne:
Value
$5.78
$5.97
1-Wochen-Bereich:
Value
$5.55
$5.99
52-Wochen-Spanne:
Value
$5.51
$12.65

Amicus Therapeutics Inc Stock (FOLD) Company Profile

Name
Firmenname
Amicus Therapeutics Inc
Name
Telefon
(609) 662-2000
Name
Adresse
47 HULFISH STREET, PRINCETON, NJ
Name
Mitarbeiter
499
Name
Twitter
@amicusrx1
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
FOLD's Discussions on Twitter

Vergleichen Sie FOLD mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
FOLD
Amicus Therapeutics Inc
5.95 1.88B 493.67M -104.69M -31.51M -0.34
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-12-13 Herabstufung Morgan Stanley Overweight → Equal-Weight
2024-09-06 Eingeleitet Jefferies Buy
2024-05-30 Eingeleitet Wells Fargo Overweight
2024-05-14 Hochstufung Guggenheim Neutral → Buy
2023-12-19 Hochstufung Morgan Stanley Equal-Weight → Overweight
2022-09-09 Eingeleitet Morgan Stanley Equal-Weight
2022-04-13 Fortgesetzt Goldman Neutral
2022-01-14 Hochstufung SVB Leerink Mkt Perform → Outperform
2021-11-15 Hochstufung Stifel Hold → Buy
2021-09-30 Hochstufung JP Morgan Neutral → Overweight
2021-07-19 Fortgesetzt BTIG Research Buy
2021-05-27 Eingeleitet Needham Hold
2021-05-21 Eingeleitet UBS Buy
2021-04-14 Hochstufung Cantor Fitzgerald Neutral → Overweight
2021-03-02 Eingeleitet Stifel Hold
2021-02-12 Herabstufung Cantor Fitzgerald Overweight → Neutral
2021-02-12 Herabstufung JP Morgan Overweight → Neutral
2020-12-28 Fortgesetzt Cantor Fitzgerald Overweight
2020-12-10 Herabstufung Citigroup Buy → Neutral
2020-11-11 Eingeleitet Berenberg Hold
2020-06-17 Eingeleitet BTIG Research Buy
2020-02-04 Fortgesetzt Cantor Fitzgerald Overweight
2019-11-12 Bestätigt H.C. Wainwright Buy
2019-06-17 Eingeleitet H.C. Wainwright Buy
2019-06-05 Bestätigt Cantor Fitzgerald Overweight
2019-04-05 Eingeleitet Janney Buy
2019-01-30 Eingeleitet Cantor Fitzgerald Overweight
2018-10-29 Eingeleitet Citigroup Neutral
2018-08-17 Herabstufung Chardan Capital Markets Buy → Neutral
2017-10-06 Fortgesetzt Goldman Neutral
2017-09-13 Bestätigt Chardan Capital Markets Buy
2017-08-10 Bestätigt Chardan Capital Markets Buy
2017-01-24 Hochstufung Robert W. Baird Neutral → Outperform
2016-05-18 Eingeleitet BofA/Merrill Buy
2016-04-14 Eingeleitet Robert W. Baird Neutral
2016-04-12 Bestätigt Chardan Capital Markets Buy
2015-09-16 Herabstufung Chardan Capital Markets Buy → Neutral
2015-06-16 Bestätigt Chardan Capital Markets Buy
Alle ansehen

Amicus Therapeutics Inc Aktie (FOLD) Neueste Nachrichten

pulisher
Jun 18, 2025

When Will Amicus Therapeutics, Inc. (NASDAQ:FOLD) Turn A Profit? - simplywall.st

Jun 18, 2025
pulisher
Jun 17, 2025

Amicus Therapeutics (NASDAQ:FOLD) Hits New 52-Week LowTime to Sell? - MarketBeat

Jun 17, 2025
pulisher
Jun 17, 2025

Amicus Therapeutics stock hits 52-week low at 5.79 USD By Investing.com - Investing.com Canada

Jun 17, 2025
pulisher
Jun 16, 2025

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives $16.22 Average Price Target from Analysts - MarketBeat

Jun 16, 2025
pulisher
Jun 14, 2025

(FOLD) Technical Data - news.stocktradersdaily.com

Jun 14, 2025
pulisher
Jun 14, 2025

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Wedge Capital Management L L P NC - MarketBeat

Jun 14, 2025
pulisher
Jun 12, 2025

Amicus Therapeutics: Opportunity Awaits In This Beaten Down Pharma (NASDAQ:FOLD) - Seeking Alpha

Jun 12, 2025
pulisher
Jun 10, 2025

Amicus Therapeutics at Goldman Sachs Conference: Strategic Insights Unveiled By Investing.com - Investing.com Canada

Jun 10, 2025
pulisher
Jun 10, 2025

Fabry Disease Market to Grow Rapidly During the Study Period (2020–2034) | DelveInsight - Yahoo Finance

Jun 10, 2025
pulisher
Jun 09, 2025

Zacks Research Issues Pessimistic Outlook for FOLD Earnings - MarketBeat

Jun 09, 2025
pulisher
Jun 05, 2025

Two Sigma Investments LP Increases Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

Jun 05, 2025
pulisher
Jun 04, 2025

Pompe Disease Therapeutic Market Deep Research Report with - openPR.com

Jun 04, 2025
pulisher
Jun 04, 2025

Millennium Management LLC Buys 44,449 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

Jun 04, 2025
pulisher
Jun 03, 2025

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

Jun 03, 2025
pulisher
Jun 03, 2025

New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

New Strong Sell Stocks for June 3rd - Yahoo Finance

Jun 03, 2025
pulisher
Jun 03, 2025

Amicus (FOLD) Reports Positive Findings from PROPEL Study in Pompe Disease | FOLD Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and Nerve - GlobeNewswire

Jun 03, 2025
pulisher
Jun 03, 2025

Clinical Data Reveals Treatment Advantages: 77% of Pompe Disease Patients Show Improvement with New Therapy - Stock Titan

Jun 03, 2025
pulisher
Jun 03, 2025

Two Sigma Advisers LP Acquires 52,000 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

Jun 03, 2025
pulisher
Jun 03, 2025

Cetera Investment Advisers Takes Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World

Jun 03, 2025
pulisher
Jun 02, 2025

How to Take Advantage of moves in (FOLD) - news.stocktradersdaily.com

Jun 02, 2025
pulisher
May 31, 2025

Man Group plc Decreases Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

May 31, 2025
pulisher
May 30, 2025

Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025 - GlobeNewswire

May 30, 2025
pulisher
May 30, 2025

Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025 | FOLD Stock News - GuruFocus

May 30, 2025
pulisher
May 30, 2025

Rare Disease Leader Amicus Therapeutics to Present Latest Updates at Major Healthcare Conferences - Stock Titan

May 30, 2025
pulisher
May 30, 2025

Millennium Management LLC Has $4.31 Million Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World

May 30, 2025
pulisher
May 30, 2025

Voloridge Investment Management LLC Sells 397,497 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

May 30, 2025
pulisher
May 28, 2025

Squarepoint Ops LLC Purchases 753,060 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

May 28, 2025
pulisher
May 28, 2025

Neo Ivy Capital Management Increases Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

May 28, 2025
pulisher
May 28, 2025

Woodline Partners LP Sells 726,952 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

May 28, 2025
pulisher
May 27, 2025

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Purchased by Ameriprise Financial Inc. - Defense World

May 27, 2025
pulisher
May 26, 2025

Pompe Disease Market: Epidemiology, Therapies, Companies, - openPR.com

May 26, 2025
pulisher
May 26, 2025

Teza Capital Management LLC Sells 68,066 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

May 26, 2025
pulisher
May 26, 2025

Nuveen Asset Management LLC Purchases 159,139 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

May 26, 2025
pulisher
May 25, 2025

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat

May 25, 2025
pulisher
May 25, 2025

297,830 Shares in Amicus Therapeutics, Inc. (NASDAQ:FOLD) Bought by Sovereign s Capital Management LLC - MarketBeat

May 25, 2025
pulisher
May 24, 2025

Vestal Point Capital LP Acquires New Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

May 24, 2025
pulisher
May 23, 2025

Deutsche Bank AG Grows Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

May 23, 2025
pulisher
May 21, 2025

Rafferty Asset Management LLC Sells 73,883 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

May 21, 2025

Finanzdaten der Amicus Therapeutics Inc-Aktie (FOLD)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Amicus Therapeutics Inc-Aktie (FOLD) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Campbell Bradley L
President and CEO
Feb 19 '25
Sale
10.00
400
4,000
1,150,657
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Kapitalisierung:     |  Volumen (24h):